The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

  1. Rodríguez, P.C.
  2. Prada, D.M.
  3. Moreno, E.
  4. Aira, L.E.
  5. Molinero, C.
  6. López, A.M.
  7. Gómez, J.A.
  8. Hernández, I.M.
  9. Martínez, J.P.
  10. Reyes, Y.
  11. Milera, J.M.
  12. Hernández, M.V.
  13. Torres, R.
  14. Avila, Y.
  15. Barrese, Y.
  16. Viada, C.
  17. Montero, E.
  18. Hernández, P.
Revista:
Clinical and Experimental Immunology

ISSN: 1365-2249,  0009-9104

Ano de publicación: 2018

Volume: 191

Número: 2

Páxinas: 229-239

Tipo: Artigo

DOI: 10.1111/CEI.13061 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus